Research programme: respiratory syncytial virus therapeutics - Alnylam/Merck

Drug Profile

Research programme: respiratory syncytial virus therapeutics - Alnylam/Merck

Alternative Names: ALN RSV02

Latest Information Update: 23 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Cubist Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Respiratory syncytial virus infections

Most Recent Events

  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 07 Jan 2011 Alnylam Pharmaceuticals and Cubist Pharmaceuticals put the paediatric Respiratory syncytial virus therapeutics programme on hold (Inhalation)
  • 27 Nov 2009 Preclinical trials in Respiratory syncytial virus infections in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top